Dr. Reddy's Laboratories Limited (NYSE: RDY) Stock Competitors & Peer Comparison
See RDY's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RDY and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RDY | $12.03 | -1.11% | 10B | 19.73 | $0.61 | +0.70% |
| TAK | $18.71 | +1.52% | 59.5B | 13.45 | $1.39 | +3.37% |
| HLN | $9.86 | -0.50% | 43.4B | 18.39 | $0.54 | +2.01% |
| TEVA | $36.62 | -2.32% | 42.6B | 12.50 | $2.93 | N/A |
| ZTS | $76.29 | +0.16% | 32B | 11.59 | $6.58 | +2.73% |
| VTRS | $16.94 | -0.88% | 19.7B | 6.72 | $2.52 | +2.83% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.42 | -1.05% | 12.2B | 23.03 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ALKS | $46.88 | -1.76% | 7.9B | 49.35 | $0.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
RDY vs TAK Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TAK has a market cap of 59.5B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TAK trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TAK's P/E ratio is 13.45. In terms of profitability, RDY's ROE is +0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, RDY is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for RDY.Check TAK's competition here
Haleon plc (NYSE: HLN)
RDY vs HLN Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while HLN trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas HLN's P/E ratio is 18.39. In terms of profitability, RDY's ROE is +0.09%, compared to HLN's ROE of +0.17%. Regarding short-term risk, RDY is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
RDY vs TEVA Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TEVA has a market cap of 42.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TEVA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TEVA's P/E ratio is 12.50. In terms of profitability, RDY's ROE is +0.09%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, RDY is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
RDY vs ZTS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ZTS has a market cap of 32B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ZTS trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ZTS's P/E ratio is 11.59. In terms of profitability, RDY's ROE is +0.09%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, RDY is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
RDY vs VTRS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while VTRS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas VTRS's P/E ratio is 6.72. In terms of profitability, RDY's ROE is +0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
RDY vs ITCI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ITCI's P/E ratio is -180.64. In terms of profitability, RDY's ROE is +0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, RDY is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
RDY vs ELAN Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ELAN trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ELAN's P/E ratio is 23.03. In terms of profitability, RDY's ROE is +0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
RDY vs CTLT Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CTLT's P/E ratio is -27.84. In terms of profitability, RDY's ROE is +0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, RDY is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for RDY.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
RDY vs ALKS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ALKS trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ALKS's P/E ratio is 49.35. In terms of profitability, RDY's ROE is +0.09%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, RDY is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
RDY vs LNTH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while LNTH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas LNTH's P/E ratio is 16.97. In terms of profitability, RDY's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, RDY is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
RDY vs AMRX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AMRX trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AMRX's P/E ratio is 19.86. In terms of profitability, RDY's ROE is +0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, RDY is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
RDY vs INDV Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while INDV trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas INDV's P/E ratio is 9.54. In terms of profitability, RDY's ROE is +0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, RDY is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for RDY.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
RDY vs RGC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas RGC's P/E ratio is -456.34. In terms of profitability, RDY's ROE is +0.09%, compared to RGC's ROE of -2.32%. Regarding short-term risk, RDY is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
RDY vs ALVOW Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ALVOW's P/E ratio is 46.65. In terms of profitability, RDY's ROE is +0.09%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, RDY is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
RDY vs SUPN Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SUPN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SUPN's P/E ratio is 14.38. In terms of profitability, RDY's ROE is +0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, RDY is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
RDY vs BHC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas BHC's P/E ratio is 1.73. In terms of profitability, RDY's ROE is +0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, RDY is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
RDY vs HCM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while HCM trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas HCM's P/E ratio is 5.29. In terms of profitability, RDY's ROE is +0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, RDY is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
RDY vs DCPH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas DCPH's P/E ratio is -11.58. In terms of profitability, RDY's ROE is +0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, RDY is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
RDY vs AVDL Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, RDY's ROE is +0.09%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, RDY is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for RDY.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
RDY vs TRLV Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TRLV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TRLV's P/E ratio is -4.88. In terms of profitability, RDY's ROE is +0.09%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, RDY is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
RDY vs PRGO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PRGO trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PRGO's P/E ratio is 5.71. In terms of profitability, RDY's ROE is +0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, RDY is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
RDY vs EMBCV Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas EMBCV's P/E ratio is N/A. In terms of profitability, RDY's ROE is +0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, RDY is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
RDY vs DVAX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas DVAX's P/E ratio is -41.89. In terms of profitability, RDY's ROE is +0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, RDY is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
RDY vs ALVO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ALVO trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ALVO's P/E ratio is -15.82. In terms of profitability, RDY's ROE is +0.09%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, RDY is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
RDY vs ETON Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ETON trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ETON's P/E ratio is 130.22. In terms of profitability, RDY's ROE is +0.09%, compared to ETON's ROE of +0.40%. Regarding short-term risk, RDY is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
RDY vs ANIP Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ANIP trades at $71.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ANIP's P/E ratio is 8.76. In terms of profitability, RDY's ROE is +0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, RDY is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
RDY vs TARO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TARO's P/E ratio is 30.05. In terms of profitability, RDY's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, RDY is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for RDY.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
RDY vs PAHC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PAHC trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PAHC's P/E ratio is 13.17. In terms of profitability, RDY's ROE is +0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, RDY is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
RDY vs HROW Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while HROW trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas HROW's P/E ratio is -38.65. In terms of profitability, RDY's ROE is +0.09%, compared to HROW's ROE of -1.04%. Regarding short-term risk, RDY is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
RDY vs CRON Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CRON's P/E ratio is 30.96. In terms of profitability, RDY's ROE is +0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, RDY is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
RDY vs AMPH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AMPH trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AMPH's P/E ratio is 8.14. In terms of profitability, RDY's ROE is +0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, RDY is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
RDY vs PCRX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PCRX trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PCRX's P/E ratio is 10.23. In terms of profitability, RDY's ROE is +0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, RDY is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
RDY vs PETQ Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PETQ's P/E ratio is 83.73. In terms of profitability, RDY's ROE is +0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, RDY is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
RDY vs COLL Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, COLL has a market cap of 768.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while COLL trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas COLL's P/E ratio is 2.97. In terms of profitability, RDY's ROE is +0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, RDY is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RDY vs IRWD Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas IRWD's P/E ratio is 5.50. In terms of profitability, RDY's ROE is +0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, RDY is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
RDY vs EVO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, EVO has a market cap of 675M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas EVO's P/E ratio is -2.68. In terms of profitability, RDY's ROE is +0.09%, compared to EVO's ROE of -0.27%. Regarding short-term risk, RDY is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
RDY vs AQST Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AQST has a market cap of 671.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AQST trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AQST's P/E ratio is -8.23. In terms of profitability, RDY's ROE is +0.09%, compared to AQST's ROE of +2.44%. Regarding short-term risk, RDY is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AQST's competition here
Glass House Brands Inc (NYSE: GLAS)
RDY vs GLAS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, GLAS has a market cap of 662.8M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while GLAS trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas GLAS's P/E ratio is -15.30. In terms of profitability, RDY's ROE is +0.09%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, RDY is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
RDY vs EOLS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, EOLS has a market cap of 596M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while EOLS trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas EOLS's P/E ratio is -28.66. In terms of profitability, RDY's ROE is +0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, RDY is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
RDY vs BDSI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas BDSI's P/E ratio is 6.82. In terms of profitability, RDY's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, RDY is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
RDY vs TLRY Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TLRY has a market cap of 506.6M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TLRY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TLRY's P/E ratio is -4.18. In terms of profitability, RDY's ROE is +0.09%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, RDY is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
RDY vs KMDA Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, KMDA has a market cap of 477.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas KMDA's P/E ratio is 21.76. In terms of profitability, RDY's ROE is +0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, RDY is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for RDY.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
RDY vs CGC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CGC has a market cap of 410.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CGC's P/E ratio is -0.59. In terms of profitability, RDY's ROE is +0.09%, compared to CGC's ROE of -0.33%. Regarding short-term risk, RDY is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
RDY vs TKNO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TKNO has a market cap of 388.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TKNO trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TKNO's P/E ratio is -23.35. In terms of profitability, RDY's ROE is +0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, RDY is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
RDY vs EBS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, EBS has a market cap of 322M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while EBS trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas EBS's P/E ratio is 4.33. In terms of profitability, RDY's ROE is +0.09%, compared to EBS's ROE of -0.36%. Regarding short-term risk, RDY is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
RDY vs ALIM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ALIM's P/E ratio is 5.28. In terms of profitability, RDY's ROE is +0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, RDY is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
RDY vs LNDC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas LNDC's P/E ratio is -4.04. In terms of profitability, RDY's ROE is +0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, RDY is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LNDC's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
RDY vs CRDL Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CRDL has a market cap of 249M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CRDL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CRDL's P/E ratio is -8.61. In terms of profitability, RDY's ROE is +0.09%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, RDY is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CRDL's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
RDY vs ACB Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ACB has a market cap of 241M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ACB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ACB's P/E ratio is -7.94. In terms of profitability, RDY's ROE is +0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, RDY is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
RDY vs SIGA Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SIGA has a market cap of 231.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SIGA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SIGA's P/E ratio is 11.96. In terms of profitability, RDY's ROE is +0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, RDY is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
RDY vs TYHT Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TYHT's P/E ratio is -1.61. In terms of profitability, RDY's ROE is +0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, RDY is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
RDY vs DERM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, DERM has a market cap of 217.4M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while DERM trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas DERM's P/E ratio is -21.35. In terms of profitability, RDY's ROE is +0.09%, compared to DERM's ROE of -0.20%. Regarding short-term risk, RDY is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
RDY vs ORGO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ORGO has a market cap of 211M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ORGO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ORGO's P/E ratio is 54.67. In terms of profitability, RDY's ROE is +0.09%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, RDY is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
RDY vs REPH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas REPH's P/E ratio is -8.04. In terms of profitability, RDY's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, RDY is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
RDY vs OGI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, OGI has a market cap of 164.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while OGI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas OGI's P/E ratio is 2.63. In terms of profitability, RDY's ROE is +0.09%, compared to OGI's ROE of +0.21%. Regarding short-term risk, RDY is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
RDY vs LFCR Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, LFCR has a market cap of 163.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while LFCR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas LFCR's P/E ratio is -4.07. In terms of profitability, RDY's ROE is +0.09%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, RDY is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
RDY vs THTX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas THTX's P/E ratio is -28.83. In terms of profitability, RDY's ROE is +0.09%, compared to THTX's ROE of +0.36%. Regarding short-term risk, RDY is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
RDY vs ASRT Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ASRT's P/E ratio is -7.10. In terms of profitability, RDY's ROE is +0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, RDY is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
RDY vs SCTL Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SCTL's P/E ratio is -7.86. In terms of profitability, RDY's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, RDY is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for RDY.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
RDY vs BGM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, BGM has a market cap of 107.8M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas BGM's P/E ratio is -0.98. In terms of profitability, RDY's ROE is +0.09%, compared to BGM's ROE of -0.05%. Regarding short-term risk, RDY is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
RDY vs PROC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PROC's P/E ratio is 1.53. In terms of profitability, RDY's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, RDY is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
RDY vs CPIX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CPIX's P/E ratio is -16.87. In terms of profitability, RDY's ROE is +0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, RDY is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
RDY vs OPTN Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas OPTN's P/E ratio is -4.42. In terms of profitability, RDY's ROE is +0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, RDY is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for RDY.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
RDY vs ZOM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ZOM's P/E ratio is -1.62. In terms of profitability, RDY's ROE is +0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, RDY is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
RDY vs GRVI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas GRVI's P/E ratio is 26.05. In terms of profitability, RDY's ROE is +0.09%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, RDY is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
RDY vs ZYBT Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, RDY's ROE is +0.09%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, RDY is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
RDY vs ZYNE Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, RDY's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, RDY is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
RDY vs SSIC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SSIC's P/E ratio is 11.93. In terms of profitability, RDY's ROE is +0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, RDY is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
RDY vs INCR Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while INCR trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas INCR's P/E ratio is -12.23. In terms of profitability, RDY's ROE is +0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, RDY is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for RDY.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
RDY vs TLPH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TLPH's P/E ratio is -3.87. In terms of profitability, RDY's ROE is +0.09%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, RDY is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
RDY vs VLNS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas VLNS's P/E ratio is -1.03. In terms of profitability, RDY's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, RDY is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
RDY vs DRRX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas DRRX's P/E ratio is -4.44. In terms of profitability, RDY's ROE is +0.09%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, RDY is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
RDY vs JUPW Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas JUPW's P/E ratio is -2.41. In terms of profitability, RDY's ROE is +0.09%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, RDY is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
RDY vs QLI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas QLI's P/E ratio is -4.92. In terms of profitability, RDY's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, RDY is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
RDY vs CPHI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CPHI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CPHI's P/E ratio is -1.97. In terms of profitability, RDY's ROE is +0.09%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, RDY is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
RDY vs RMTI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while RMTI trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas RMTI's P/E ratio is -5.96. In terms of profitability, RDY's ROE is +0.09%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, RDY is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
RDY vs HEXO Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas HEXO's P/E ratio is -0.26. In terms of profitability, RDY's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, RDY is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
RDY vs TXMD Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, TXMD has a market cap of 25.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while TXMD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas TXMD's P/E ratio is 114.11. In terms of profitability, RDY's ROE is +0.09%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, RDY is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
RDY vs AYTU Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AYTU's P/E ratio is -1.19. In terms of profitability, RDY's ROE is +0.09%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, RDY is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for RDY.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
RDY vs CYTH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CYTH's P/E ratio is -0.80. In terms of profitability, RDY's ROE is +0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, RDY is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
RDY vs EVOK Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas EVOK's P/E ratio is -7.97. In terms of profitability, RDY's ROE is +0.09%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, RDY is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for RDY.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
RDY vs OPTH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, OPTH has a market cap of 15.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while OPTH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas OPTH's P/E ratio is -17.24. In terms of profitability, RDY's ROE is +0.09%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, RDY is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
RDY vs ACRX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ACRX's P/E ratio is -0.31. In terms of profitability, RDY's ROE is +0.09%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, RDY is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
RDY vs CABR Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, CABR has a market cap of 11.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while CABR trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas CABR's P/E ratio is -2.29. In terms of profitability, RDY's ROE is +0.09%, compared to CABR's ROE of -3.86%. Regarding short-term risk, RDY is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
RDY vs AGRX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas AGRX's P/E ratio is -0.89. In terms of profitability, RDY's ROE is +0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, RDY is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
RDY vs NLTX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas NLTX's P/E ratio is -0.28. In terms of profitability, RDY's ROE is +0.09%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, RDY is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check NLTX's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
RDY vs GELS Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, GELS has a market cap of 7.9M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while GELS trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas GELS's P/E ratio is -1.72. In terms of profitability, RDY's ROE is +0.09%, compared to GELS's ROE of -0.25%. Regarding short-term risk, RDY is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check GELS's competition here
Lannett Company, Inc. (NYSE: LCI)
RDY vs LCI Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas LCI's P/E ratio is -0.04. In terms of profitability, RDY's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, RDY is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
RDY vs ADMP Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ADMP's P/E ratio is -0.08. In terms of profitability, RDY's ROE is +0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, RDY is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
RDY vs YCBD Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, YCBD has a market cap of 5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas YCBD's P/E ratio is -1.17. In terms of profitability, RDY's ROE is +0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, RDY is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
RDY vs MNK Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas MNK's P/E ratio is -0.44. In terms of profitability, RDY's ROE is +0.09%, compared to MNK's ROE of -0.36%. Regarding short-term risk, RDY is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for RDY.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
RDY vs FLGC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas FLGC's P/E ratio is -0.19. In terms of profitability, RDY's ROE is +0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, RDY is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
RDY vs UPC Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while UPC trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas UPC's P/E ratio is -0.54. In terms of profitability, RDY's ROE is +0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
RDY vs SBFM Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SBFM has a market cap of 2.6M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SBFM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SBFM's P/E ratio is -0.18. In terms of profitability, RDY's ROE is +0.09%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, RDY is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
RDY vs PLXP Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas PLXP's P/E ratio is -0.22. In terms of profitability, RDY's ROE is +0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, RDY is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
RDY vs ATNX Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas ATNX's P/E ratio is -0.02. In terms of profitability, RDY's ROE is +0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, RDY is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
RDY vs RDHL Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas RDHL's P/E ratio is 0.14. In terms of profitability, RDY's ROE is +0.09%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, RDY is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
RDY vs SNOA Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SNOA's P/E ratio is -1.12. In terms of profitability, RDY's ROE is +0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, RDY is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
RDY vs SHPH Comparison September 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10B. In comparison, SHPH has a market cap of 2M. Regarding current trading prices, RDY is priced at $12.03 on the NYSE, while SHPH trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 19.73, whereas SHPH's P/E ratio is -0.16. In terms of profitability, RDY's ROE is +0.09%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, RDY is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SHPH's competition here